Synthetic hCG Metabolite May Fight Kaposi Sarcoma
Researchers are developing a synthetic version of HIP metabolite to treat Kaposi sarcoma.
Diagnosis & Disease Information
A Closer Look at Two Common Types of Skin Cancer
The start of the “sun-worshipping season” is a good time to review the basics of basal cell and squamous cell carcinomas.
HCV Reactivation Doesn’t Worsen Survival in HIV+ Lymphoma Patients
Study results indicate that reactivation of the hepatitis C virus (HCV) in HIV-positive patients with lymphoma does not worsen survival outcomes.
Siltuximab Indicated in HIV-, HHV-8-negative Multicentric Castleman’s Disease
CHICAGO, IL—Siltuximab, a novel chimeric anti−interleukin-6 monoclonal antibody, is active in patients with multicentric Castleman’s disease (MCD) who have had insufficient response to or failed previous therapies.
FDA Approves First Drug for Multicentric Castleman’s Disease
Janssen Biotech announced that the FDA has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman’s disease (MCD) who are HIV negative and HHV-8 negative.
Might Nano-oncology Resurrect Old Anticancer Drugs?
Nanopharmaceutical formulations might allow newly widespread adoption of old anticancer agents, with reduced toxic effects.
RiBVD Benefits Elderly with Untreated Mantle Cell Lymphoma
RiBVD regimen appears effective in elderly patients with untreated mantle cell lymphoma.
Siltuximab Offers ‘Durable’ Tumor and Symptom Responses in Multicentric Castleman’s Disease
Siltuximab improves symptoms and clinical outcomes for patients with multicentric Castleman’s disease, despite a high rate of drug discontinuation due to toxicities, according to data presented at ASH 2013.
Early Stem Cell Transplants Beneficial for Some Patients with Non-Hodgkin’s Lymphoma
Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival.
Low-Intensity Therapy Highly Effective for Treatment of Burkitt’s Lymphoma
Standard and low-dose EPOCH-R treatment results in high rates of disease-free, overall survival in patients with Burkitt’s lymphoma.
- Loading...
Loading...
Loading... 
Loading...